MX2022012618A - Aptameros para uso en el tratamiento de infecciones por coronavirus. - Google Patents

Aptameros para uso en el tratamiento de infecciones por coronavirus.

Info

Publication number
MX2022012618A
MX2022012618A MX2022012618A MX2022012618A MX2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A MX 2022012618 A MX2022012618 A MX 2022012618A
Authority
MX
Mexico
Prior art keywords
coronaviridae
viruses
family
aptamers
treatment
Prior art date
Application number
MX2022012618A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Wallukat
Annekathrin Haberland
JOHANNES MüLLER
Peter Göttel
Original Assignee
Berlin Cures GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Cures GmbH filed Critical Berlin Cures GmbH
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of MX2022012618A publication Critical patent/MX2022012618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2022012618A 2020-04-09 2021-04-09 Aptameros para uso en el tratamiento de infecciones por coronavirus. MX2022012618A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20176023 2020-05-22
EP20180781 2020-06-18
EP20204036 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (1)

Publication Number Publication Date
MX2022012618A true MX2022012618A (es) 2022-11-07

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012618A MX2022012618A (es) 2020-04-09 2021-04-09 Aptameros para uso en el tratamiento de infecciones por coronavirus.

Country Status (11)

Country Link
US (1) US12606828B2 (enExample)
EP (1) EP4133083A1 (enExample)
JP (1) JP2023521361A (enExample)
KR (1) KR20220166337A (enExample)
CN (1) CN115768895A (enExample)
AU (1) AU2021252151A1 (enExample)
BR (1) BR112022020439A2 (enExample)
CA (1) CA3175067A1 (enExample)
IL (1) IL297155A (enExample)
MX (1) MX2022012618A (enExample)
ZA (1) ZA202212179B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3007984T3 (en) * 2021-04-09 2025-03-21 Berlin Cures GmbH Aptamers for use in the treatment of coronaviridae infections
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 SARSCoV2의 외피 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508473A (ja) * 2005-08-26 2009-03-05 アーケミツクス・コーポレイシヨン 高親和性でトロンビンに結合するアプタマー
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
KR102596343B1 (ko) * 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)

Also Published As

Publication number Publication date
US12606828B2 (en) 2026-04-21
BR112022020439A2 (pt) 2022-11-29
IL297155A (en) 2022-12-01
JP2023521361A (ja) 2023-05-24
AU2021252151A1 (en) 2022-12-08
CA3175067A1 (en) 2021-10-14
CN115768895A (zh) 2023-03-07
ZA202212179B (en) 2025-03-26
KR20220166337A (ko) 2022-12-16
EP4133083A1 (en) 2023-02-15
US20230140490A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2023001949A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020)
MX2022013301A (es) Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
CL2022002951A1 (es) Composiciones de arni del factor b del complemento (cfb) y métodos para su uso.
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX360728B (es) Metodos y composiciones para virus vivos atenuados.
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2023001681A2 (es) Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
ZA202212179B (en) Aptamers for use in the treatment of coronaviridae infections
CL2022003390A1 (es) Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
CL2025003288A1 (es) Anticuerpos que se unen a ox40l y métodos de uso.
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17
AR083546A1 (es) Tratamiento de inflamacion gastrointestinal, soriasis y asma
MX2022015365A (es) Composiciones y métodos para el tratamiento del covid largo.
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
MX2022009776A (es) Tratamiento de la colangitis biliar primaria con elafibranor.
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.